The Filing Desk

HeartFlow

HTFL · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

HTFL · Last close · November 13, 2026
$48.46
Value HeartFlow yourself

HeartFlow's revenue rose 39.9% to $176 million in fiscal 2025. Its operating margin was −36.4%, up from −48.7% a year earlier. Free cash flow was −$59 million. The diluted share count rose 587.1%.

Heartflow, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 18, 2026 · 0001464521-26-000042 Updated
Revenue
$176M
39.9%
Operating margin
−36.4%
12.3 pts
Net income
−$117M
 
Free cash flow
−$59M
 
Return on equity
—
 
Market cap
$4.2B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What HeartFlow does

Heartflow sells software and artificial intelligence (AI) that help doctors diagnose and manage coronary artery disease (CAD), in which plaque builds up in the heart's arteries and restricts blood flow. Its platform takes a heart scan known as a coronary CT angiogram and builds a personalized 3D model of the patient's heart. From the model, it shows how blood flows, how narrow the arteries are, and how much plaque there is and what it is made of.

Heartflow says its platform has been used to assess CAD in more than 600,000 patients. Its revenue comes almost entirely from one product, Heartflow FFR CT Analysis. A newer product, Heartflow Plaque Analysis, is still at an early stage of sale.

The company competes with traditional tests for CAD, such as stress tests, and says its approach is more accurate. Its sales depend on hospitals and other providers changing how they evaluate CAD and on insurers paying for the analysis. It has a concentrated customer base.

Its biggest risks, as it describes them

  • Almost all its revenue comes from one product, Heartflow FFR CT Analysis.
  • Healthcare providers may be unwilling to change how they evaluate coronary artery disease.
  • Insurers and government payors may not cover or pay enough for the platform.
  • It has a concentrated customer base and has lost money since it began.
  • Its AI models may have errors or create legal and reputational problems.
From HeartFlow's annual report on Form 10-K, filed March 18, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

HeartFlow lost money in fiscal 2025: a net loss of $117 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments12351280
Debt incl. finance leases———
Net debt (negative means net cash)———
Net debt to EBITDA———
Debt to equity———
Interest coverage−3.0x−2.7x−4.2x
Current ratio—2.5x5.2x
Quick ratio—2.5x5.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project HeartFlow's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What HeartFlow says to expect

  • Full year 2026: total revenueTotal revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year)
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 12, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $1.1 million of HeartFlow shares on the open market, and 6 insiders sold $138.1 million, $23.1 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 18, 2026Campbell RogersChief Medical OfficerSold plan19,682$50.15$987,052Form 4
Sep 18, 2026Vikram VergheseChief Financial OfficerSold plan16,766$50.75$850,874Form 4
Sep 17, 2026Vikram VergheseChief Financial OfficerSold plan7,579$50.11$379,784Form 4
Sep 15, 2026Vikram VergheseChief Financial OfficerSold plan668$50.01$33,407Form 4
Sep 14, 2026Vikram VergheseChief Financial OfficerSold plan4,593$50.24$230,752Form 4
Sep 11, 2026Vikram VergheseChief Financial OfficerSold plan29,714$50.06$1.5 millionForm 4
Sep 11, 2026John C.M. FarquharChief Executive Officer, DirectorSold plan3,890$50.00$194,500Form 4
Sep 10, 2026John C.M. FarquharChief Executive Officer, DirectorSold plan35,010$46.42$1.6 millionForm 4
Sep 8, 2026Vikram VergheseChief Financial OfficerSold plan6,640$50.03$332,199Form 4
Sep 3, 2026Vikram VergheseChief Financial OfficerSold plan27,540$49.69$1.4 millionForm 4
Sep 2, 2026Vikram VergheseChief Financial OfficerSold plan5,876$50.60$297,326Form 4
Aug 21, 2026John C.M. FarquharChief Executive Officer, DirectorSold plan27,230$50.00$1.4 millionForm 4
The latest 12 of 36 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 40−14.0%6.4%
Altman Z''−31.75−2.45
Accruals ratio—−26.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positive—Fail
Cash from operations is positiveFailFail
Return on assets rose——
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rose—Pass
Share count didn't riseFailFail
Gross margin rosePassPass
Revenue rose relative to assets——
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put HeartFlow side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
HeartFlowFY2539.9%−36.4%−33.5%———
Omada HealthFY2553.2%−4.6%6.5%———Compare
HealthStreamFY254.3%6.7%19.6%———Compare
CertaraFY258.8%5.0%22.6%0.9%1.1x5Compare
PhreesiaFY2614.5%−1.4%14.1%−2.2%−2.6x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue87126176
Revenue growth—44.3%39.9%
Gross profit5894135
Research and development364465
Operating income−73−61−64
Net income−96−96−117
Diluted EPS (US$)−25.32−17.98−3.17
Diluted shares (millions)5537
Cash flow
Cash from operations−76−69−54
Capital expenditure645
Free cash flow−83−73−59
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation121014
Balance sheet at fiscal year end
Cash and short-term investments12351280
Debt incl. finance leases———
Total assets—119360
Total liabilities—21059
Shareholders' equity−778−860301
Margins and ratios
Gross margin66.6%75.1%76.8%
Operating margin−83.6%−48.7%−36.4%
Net margin−109.7%−76.7%−66.3%
Free cash flow margin−94.7%−58.3%−33.5%
Rule of 40 (growth + FCF margin)—−14.0%6.4%
Return on capital———
Return on equity———
Return on assets——−48.9%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: HeartFlow's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with HeartFlow.